Pulthera to Raise $100M for Further Development of ARDS Therapeutic in COVID-19 Patients

Pulthera is raising $100 million dollars to advance the following objectives:

  • Complete the FDA approved Phase II-A clinical trial for COVID-19 Cytokine Storm Blocker
  • Implement Phase II-B / Phase III clinical trial for ARDS in COVID-19 patients
  • Accelerate commercial manufacturing capabilities
  • Advance the clinical application of at least one other lung-related medical condition beyond ARDS in COVID-19 patients

The Company seeks to leverage its proprietary technology and therapeutics to become a global leader in the pulmonary, respiratory and lung-health field.